Accelerating Hydropower Cohort 2: Empowering 12 New Sui Projects with Expert Guidance and Strategic Partnerships

The Hydropower Accelerator Cohort 2 has empowered 12 new Sui projects, providing curated sessions, mentorship, and resources. The program focuses on emerging technology, tokenomics, go-to-market strategy, and branding. The participating teams have formed strategic partnerships and are now live on Sui Mainnet or scaling rapidly, actively raising strategic rounds. The projects include Dexter, Lemon Farm Labs, Newmoney, NODO, Pawtato, RaidenX, River, Sage Protocol, talentum, Unexia, and more.

Amgen Inc. (NASDAQ: AMGN) has announced the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate administered subcutaneously monthly or less frequently. The study demonstrated significant weight loss in individuals with obesity, both with and without Type 2 diabetes (T2D), compared to placebo.

In the Phase 2 study, MariTide achieved up to approximately 20% average weight loss in people living with obesity without T2D, compared to 2.6% in the placebo arm. Among those with T2D, MariTide resulted in up to 17% average weight loss, compared to 1.4% in the placebo group. The study also showed sustained reductions in hemoglobin A1c (HbA1c) and improvements in cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP), and select lipid parameters [1].

No new safety signals were identified in the Phase 2 study, and tolerability was consistent with the GLP-1 class. Gastrointestinal (GI) events were the most frequently reported adverse events, but they were predominantly limited to initial dosing and less frequent with dose escalation. Discontinuation rates due to GI AEs in the dose escalation arms were lower than in non-dose escalation arms [1].

The Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, also presented at the 85th American Diabetes Association (ADA) Scientific Sessions, assessed lower starting doses of MariTide and used the MINVR reporting tool to evaluate different dose escalation schedules. The primary analysis showed that participants receiving 21 mg/70 mg/350 mg had an overall incidence of vomiting of 24.4%, and those receiving 35 mg/70 mg/350 mg had an overall incidence of vomiting of 22.5% [1].

Data from these studies informed the Phase 3 MARITIME program, which recently initiated 72-week chronic weight management studies to evaluate MariTide's safety, efficacy, and tolerability in participants with obesity or overweight, with and without T2D. The studies will evaluate three target doses, each with an initial starting dose of 21 mg, followed by 35 mg and then 70 mg, over an eight-week dose escalation period [1].

Amgen also expects to initiate Phase 3 clinical outcomes studies for atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF), as well as a Phase 3 study for obstructive sleep apnea (OSA) in 2025 [1].

References:
[1] https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/Amgen-Announces-Full-Results-from-Part-1-of-the-Phase-2-Study-of-MariTide-50315288/